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Abstract
Introduction: Osteoporosis poses significant risk for HIV infected subjects in the era of the long-term antiretroviral treatment. For this 
study frequency of the selected 11 single nucleotide polymorphisms (SNP single nucleotide polymorphism) previously associated with 
osteoporosis risk in HIV infected and uninfected cohorts was analysed. Association with the SNP variation and the risk of osteoporosis 
in the entire study and in HIV-infected cases was investigated.
Material and methods: The study included 568 patients (226 women and 342 men): 315 HIV-infected patients and 253 anti-HIV negative 
cases. Osteoporosis was confirmed using dual energy absorptiometry ionizing radiation (DXA) in eight HIV infected patients and three 
controls [odds ratio (OR): 7.66, 95% CI: 1.98–29.6; p = 0.001; relative risk (RR): 7.04, 95% CI: 1.98–25.97, p = 0.0019]. SNP assays performed 
for collagen type 1 (COL1A1) rs1800012, parathyroid hormone (PTH) rs9630182, estrogen receptor gene (ER1) rs2077647, rs3020314 and 
rs1884051, Vitamin D receptor (VDR) rs1544410 and rs731236, Osteoprotegerin rs4355801, LDL receptor protein (LRP5) rs3736228, RANK 
rs3018362 and CYP19A1 (aromatase) rs700518 using TaqMan SNP Genotyping Assay (Applied Biosystems) according to the manufacturer’s 
protocol. For statistics Statistica 12 software was used.
Results: Majority of allele frequencies for the studied polymorphisms were consistent with the Hardy-Weinberg equilibrium. CC homozy-
gotes for ER1 rs2077647 were notably more common in HIV (+) cases compared to controls [OR: 2.29, 95%CI: 1.25–4.19, p = 0.003; RR: 2.11, 
1.22–3.68, p = 0.0072]. Also GG homozygotes for ER1 rs1884051 were more common both in HIV(+) [OR: 2.57, 1.33–4.94, p = 0.0016; RR: 2.37, 
1.29–4.36, p = 0.002] and in all patients with osteoporosis [OR 5.04, 1.24–20.4, p = 0.025; RR 3.94, 1.38–11.24, p = 0.043] . Additionally, in HIV 
(+) patients parathyroid hormone rs9630182 T allele was notably more common [OR: 1.4, 1.0–1.97, p = 0.024; RR: 1.15, 0.99–1.33, p = 0.029].
Conclusions: Genetic variability for the osteoporosis-associated SNPs was similar in HIV-infected patients and uninfected persons. 
ER1rs1884051 variants may be associated with the increased osteoporosis risk, but increased incidence of osteoporosis in HIV-infected 
compared to uninfected people seems to be weakly associated with investigated single nucleotide polymorphisms. Variation in the gene 
for the estrogen receptor ER1rs1884051 was significantly more frequent in patients with osteoporosis and more common in HIV infection. 
(Endokrynol Pol 2017; 68 (4): 541–549)
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Streszczenie
Wstęp: Osteoporoza staje się istotnym zagrożeniem dla pacjentów zakażonych HIV, szczególnie w erze długotrwałego leczenia antyret-
rowirusowego. W badaniu oceniono częstość wybranych 11 polimorfizmów pojedynczych nukleotydów (single nucleotide polymorphism, 
SNP) związanych z osteoporozą u pacjentów zakażonych HIV i bez tego zakażenia. Zbadano, czy zmienność genetyczna wybranych 
SNP wpływa na ryzyko osteoporozy w całej badanej populacji i u zakażonych HIV. 
Materiał i metody: Do badania włączono 568 osób (226 kobiet i 342 mężczyzn): 315 pacjentów zakażonych HIV i 253 osoby anty-HIV 
ujemne. Osteoporozę potwierdzono w badaniu za pomocą absorpcjometrii podwójnej energii promieniowania jonizującego (Dual-energy 
X-ray absorptiometry, DXA) u 8 pacjentów zakażonych HIV i 3 z grupy kontrolnej [iloraz szans (odds ratio, OR): 7,66; 95% Cl: 1,98–29,6; 
p = 0,0010; ryzyko względne (relative risk, RR): 7,04; 95% Cl: 1,98–25,97; p = 0,0019]. Zbadano SNP dla genów: kolagenu typu I (COLIA1) 
rs1800012, parathormonu (PTH) rs9630182, receptora estrogenów typu 1 (ER1) rs2077647 rs3020314 i rs1884051, receptora witaminy D (VDR) 
rs1544410 i rs731236, osteoprotegeryny (OPG) rs4355801, białka receptorowego dla LDL (LRP5) rs3736228, RANK rs3018362 i aromatazy 
(CYP19A1) rs700518 przy użyciu zestawów TaqMan SNP Genotyping Assay (AppliedBiosystems) zgodnie z protokołem producenta. 
Wyniki uzyskanych badań opracowano statystycznie w programie Statistica 12. 
Wyniki: Częstości alleli większości badanych polimorfizmów były zgodne z prawem Hardy-Weinberga. Analizując występowanie poszc-
zególnych genotypów, stwierdzono istotnie częstsze wstępowanie u zakażonych HIV w porównaniu z grupą kontrolną homozygoty CC 
ER1 rs2077647 (OR: 2,29; 1,25–4,19; p = 0,003; RR: 2,11; 1,22–3,68; p = 0,0072). Także częściej występowała homozygota GG ER1 rs1884051 
u zakażonych HIV (OR: 2,57; 1,33–4,94; p = 0,0016; RR: 2,37; 1,29–4,36; p = 0,002) oraz u pacjentów z osteoporozą (OR: 5,04; 1,24–20,4; 
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p = 0,025; RR: 3,94; 1,38–11,24; p = 0,043). Dodatkowo u pacjentów zakażonych HIV istotnie częściej (p = 0,047) występował allel T genu 
parathormonu rs9630182 (OR: 1,4; 1,0–1,97; p = 0,024; RR: 1,15; 0,99–1,33; p = 0,029).
Wnioski: Zmienność genetyczna pojedynczych nukleotydów związanych z występowaniem osteoporozy była podobna u pacjentów 
zakażonych HIV i osób niezakażonych. Warianty ER1 rs1884051 mogą mieć związek ze zwiększonym ryzykiem osteoporozy, ale wyższe 
ryzyko osteoporozy u pacjentów zakażonych HIV w porównaniu z osobami niezakażonymi wydaje się mieć niewielki związek z badanymi 
polimorfizmami pojedynczych nukleotydów. Zmienność w genie dla receptora estrogenów ER1rs1884051 istotnie częściej wystąpiła 
u pacjentów z osteoporozą i u zakażonych HIV. (Endokrynol Pol 2017; 68 (4): 542–549)
Słowa kluczowe: polimorfizm, SNP, osteoporoza, HIV
Introduction 
Osteoporosis is a chronic, multifactorial metabolic 
disease manifesting in the decreased bone mineral 
density. It was defined by WHO as the decrease of the 
bone mineral density in the dual energy absorptiometry 
ionizing radiation (DXA) scanning by more than 2.5 
standard deviations from the mean for the reference 
population (BMD — bone mineral density: T-score 
> –2.5). Consequences include increased frequency 
of bone fractures, decreased quality of life and higher 
likelihood of death. 
Decrease in the bone density is a natural con-
sequence of aging. It was estimated, that from the 
second half of the third decade of life an average 
individual would lose from 0.5 to 1% of a body mass 
per year. Most active research on this important issue 
was performed on the post-menopausal women: in 
this period of life tempo of bone demineralization is 
accelerating due to estrogen deficiency. It was also 
proven, that the other risk factors such as wasting, 
age > 65 years, calcium absorption disturbances, 
vitamin D3 deficiency, excessive coffee, alcohol or 
coca-cola consumption, as well as cigarette smok-
ing, long term immobilization, steroid treatment of 
> 3 month duration, family history of low-energy 
fractures, etc., play a key role in the pathogenesis of 
this disease. Osteoporosis as a secondary disease may 
be associated with hyperparathyroidism, hyperthy-
roidism, diabetes, and higher risk of neoplasm devel-
opment. It has been reported, that HIV infection is 
an independent risk factor of osteoporosis, especially 
in the era of usually lifelong, antiretroviral therapy 
(ART) [1–4]. HIV infection might be perceived as 
a generalized, long-term inflammatory process with 
loss of T helper lymphocytes of a CD4 phenotype. 
Clinical symptoms of advanced immunodeficiency 
among HIV infected patients manifest by an array of 
opportunistic infections and neoplasms, defining an 
acquired immunodeficiency syndrome (AIDS). Since 
the beginning of HIV pandemics increased preva-
lence of osteopenia and/or osteoporosis among in-
fected individuals has been observed [1, 4, 5]. Prior to 
the antiretroviral treatment era, observations of this 
phenomenon had been performed on small groups of 
survivors, with osteoporosis diagnosed in a low per-
centage of patients, mainly young men. From the time 
of introduction of the combined antiretroviral treat-
ment (cART) in 1996, osteoporosis or osteopenia has 
been described in an increasing proportion of treated 
patients. Prevalence of osteopenia was defined in as 
many as 60%, while osteoporosis in 10–15% of cART 
treated individuals living with HIV today [4]. Patho-
mechanism of this phenomenon remains unclear 
and is most likely multifactorial. Several hypotheses 
exist, however the most important include association 
between HIV infection of osteoblast and osteoclast 
precursors and decrease in its population, chronic 
activation of T lymphocytes as well as increase in 
the concentration of the pro-inflammatory cytokines 
such as TNF and IL-6 stimulating bone remodeling, 
hormonal disturbances — mainly decreased secre-
tion of the anabolic hormones, malnutrition and 
nutritional deficiencies — such as vitamin D3 and 
calcium deficiency related to the malabsorption and 
chronic gastrointestinal infections among individuals 
with immunodeficiency and adverse effects of the 
antiretroviral therapy [3].
Bone is a living tissue, constantly undergoing 
resorption and synthesis. Bone mineral density is 
dependent on the balance between these two pro-
cesses. Bone remodeling is directly associated with 
osteoclastogenesis and osteoblastogenesis. In this 
process genetic variability influencing various steps of 
this pathway seems to be of a vital importance [6, 7]. 
There is a well studied association between the he-
reditary marble bone disease (Albers — Schönberg 
disease) and deletion in the region coding for the NFκB 
transcription factor or associations between several 
single nucleotide polymorphisms (SNPs) such as the 
ones in the OPG gene (rs4355801) and LRP-5 gene 
(rs3736228) with decreased bone mineral density and 
increased osteoporosis risk, including osteoporotic 
bone fractures, in three cohorts in the Western Eu-
rope [6]. Osteoporosis was found to be a multilocus 
disease, as no single gene was found to be associated 
with this abnormality [8–12]. It is widely considered 
that an array of genetic factors influences both bone 
543
Endokrynologia Polska 2017; 68 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
synthesis and its metabolism [13–16]. Genetic labora-
tories in Europe and the USA have formed a consor-
tium for the study of the genetic factors associated 
with osteoporosis — GEFOS — Genetic Factors For 
Osteoporosis Consortium. As a result, in 2009 a list of 
20 SNPs associated with osteoporosis and increased 
risk of fractures was published [17]. Several groups 
of candidate genes related to the increased risk of 
osteoporosis were identified so far (presented below 
according to the type of coded protein):
 — genes coding for interleukins: interleukin-6 and 
interleukin-1;
 — genes coding for growth factors: tumor necrosis fac-
tor — TNF-α (chromosome 3), colony stimulating 
factor — CSF-1 (chromosome 12);
 — genes coding for components of the protein matrix: 
collagen type I (chromosome 17);
 — genes coding for calcitropic hormones and their 
receptors;
• vitamin D3 receptor (chromosome 12),
• estrogen receptor (chromosome 16),
• parathyroid hormone (chromosome 7);
 — Genes coding for osteoprotegerin ( chromosome 
8), NFκB (RANK) receptor activator, LDL receptor 
protein (LRP5) ( chromosome 11) etc. 
This genetic variability, associated with increased 
osteoporosis risk in various populations and ethnicities 
has been described in several SNP databases, however 
no uniform haplotype for osteoporosis have been de-
fined yet. In Poland results of several studies on such 
variability have been published so far — COLIA1 inves-
tigating collagen genetic variants as well as studies for 
the vitamin D receptor [18, 19]. Research on association 
between genotypic data and the phenotype is of the 
highest value e.g. studies on the genetic variability of 
the receptor, hormone levels and bone mineral density 
[20–35]. Of note, no such research was performed in 
HIV(+) population. 
The aim of this study was to analyse the frequency of 
osteoporosis of the well defined cohort of HIV-infected 
patients in comparison to the healthy controls and to 
investigate the genetic risk associated with osteoporosis/ 
/osteopenia in the analysed cohorts based on the array 
of selected SNPs. 
Material and methods
The study included two groups of adults:
Group 1 — cross-sectional cohort of 315 study individuals 
with confirmed HIV infection, followed-up at the Depart-
ment of Infectious Diseases and Hepatology, Pomeranian 
Medical University, Szczecin, Poland. To reflect current 
demographics of HIV infection in Poland the study group 
included 91 (29%) women and 224 (79%) men. 
Group 2 — controls — which included 253 persons: 
115 (45%) women and 118 (55%) men, with HIV infec-
tion excluded in the screening test (rapid HIV test of 
a single blood sample: TOYO Anti- HIV1/2 test (Turklab 
Tibbi Malzemeler San. Turkey; sensitivity for European 
population of 99.8%, specificity of 99.9%). 
All patients provided a formal written consent prior 
to the inclusion into the study. 
The study procedures included the following: 
1. Medical history and examination, body mass index 
(BMI) calculation. 
2. Substudy of the bone mineral density assessment 
(BMD) for the lumbar spine and femoral neck using 
a LUNAR Prodigy ADVANCE scanner equipped 
with ENCORE 2007 software v.11.40.004 (GE Health-
care, Great Britain) was performed in 87 HIV in-
fected persons and in 230 cases from control group.
3. The genetic analyses were performed in all partici-
pants of study (568 pts) at the laboratory of Infec-
tious Diseases and Hepatology, Pomeranian Medical 
University, Szczecin. For the DNA extraction sam-
ples of full blood, collected into the tubes containing 
EDTA coagulant were used. To ensure data safety 
every sample was coded by the unique number. 
DNA was extracted using QIAamp DNA blood mini 
kit isolation columns produced by QIAgen (Hilden, 
Germany) according to the manufacturer’s proto-
col. All work with unprocessed blood samples was 
performed under the laminar flow hood to ensure 
maximum personal safety and reduce the risk of 
contamination. Genomic DNA was suspended in 
a buffer included in the kit and stored for analyses 
at 4°C.
For association studies included in this project 
eleven single nucleotide polymorphisms were selected, 
as presented in the Figure 1 and Table I (in the table com-
mon name of the coded variant is presented, GenBank 
accession number for the SNP (rs) as well as catalogue 
assay number. TaqMan SNP (Life Technologies, USA) 
genotyping assays were used according to the manu-
facturer’s protocol with real-time PCR technology on 
the StepOne thermal cycler (Applied Biosystems/Life 
Technologies, Foster City, CA). Genotypes were called 
using TaqMan Genotyper Software v1.0.1 (Applied Bio-
systems/Life Technologies, Foster City, CA), calculation 
of Hardy-Weinberg equilibrium for each analysed set of 
genotypes was performed by this software. 
For statistics Statistica12 software (Statsoft, Poland) 
was used. Statistical testing included the analyses of the 
differences in the frequency of the investigated genetic 
variants in HIV infected individuals and healthy control 
and association between the genotypes and haplotype 
and the osteoporosis risk were performed using Chi- 
-square tests.
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Results
Demographic characteristics and selected clinical study 
groups are presented in Table II. The study participants 
were of Caucasian origin and of the young age. As the 
control group enrollment focused on the individuals 
< 35 years of age to reflect the characteristics of the 
HIV-infected population in Poland the ultimate age 
of the control group was significantly lower, and the 
BMI higher compared to the people infected with HIV. 
Antiretroviral treatment (ARV) was initiated in 79% 
HIV infected cases prior to enrollment to the study. 
Bone mineral density assessment was scheduled for 
all participants in the study but performed only in the 
subset of cases who consented: 87 (28%) HIV-infected 
patients and 230 (91%) control subjects. Osteoporosis 
with confirmed in DXA T-score value < –2.5 was noted 
in 8 (9%) HIV-infected patients and 3 (1%) control group 
cases. The relative risk of osteoporosis in HIV-infected 
patients was 7-fold higher compared to the control 
group (RR = 7.04, p = 0.0019). 
Genetic testing was performed in all study partici-
pants: 568 patients (315 HIV-infected and 253 control 
subjects). The frequencies of the genotypes tested 
were consistent with the Hardy-Weinberg equilibrium 
(HWE) except for the type 1 collagen rs1800012 and 
parathyroid hormone genotypes and parathyroid hor-
mone rs9630182 with the expected frequencies notably 
different from the ones found in the analysed cohorts. 
However, the frequencies of minor allele (MAF — minor 
allele frequency) for individual SNPs were similar in the 
analyzed groups and when compared to a reference 
frequencies according to the NCBI SNP database (The 
National Center for Biotechnology Information, US 
National Library of Medicine) [36]. The results are sum-
marized in Table III.
Analyzing the differences in the prevalence of vari-
ous genotypes and alleles among HIV-infected versus 
the control group and in patients with confirmed or 
excluded osteoporosis statistically significant differ-
ences associated with the studied SNPs were found for 
the ER1, PTH and COL1A1 (borderline significant). The 
results are shown in Table IV.
In HIV patients genotype CC of the ER1 gene 
(rs2077647) proved to be significantly more frequent: 
OR = 2.29, p = 0.003. Also ER1(rs1884051) GG geno-
type or T allele of the PTH (rs9630182) were notably 
more common among HIV-1 infected cases compared 
to controls: OR = 2.57, p = 0.0016 and ; OR = 1.4, 
Figure 1. Single Nucleotide Polymorphisms selected for the study 
of association between human genetic variability and osteoporosis
Rycina 1. Polimorfizmy pojedynczych nukleotydów wybrane 
na podstawie badań nad związkiem zmienności genetycznych 
z osteoporozą
Table I. Single Nucleotide Polymorphisms selected for the 
study of association between human genetic variability and 
osteoporosis
Tabela I. Polimorfizmy pojedynczych nukleotydów wybrane 
na podstawie badań nad związkiem zmienności genetycznych 
z osteoporozą
Gene name rs Assay ID 
(APPLIEDBIOSYSTEMS)
COL1A1 rs1800012 C___7477170_30
VDR rs1544410 C___8716062_10
VDR rs731236 C___2404008_10
ER1 rs2077647 C__11414978_10
ER1 rs3020314 C__11555860_10
ER1 rs1884051 C__11918415_10
TNFRSF11B (OPG) rs4355801 C__11869235_10
PTH rs9630182 C__26485235_10
LRP5 rs3736228 C__25752205_10
RANK rs3018362 C__15763310_10
CYP19A1 (aromatase) rs700518 C___8794675_30
Table II. Demographic and clinical characteristics of study 
groups
Tabela II. Charakterystyka demograficzna i kliniczna 
badanych
Character HIV-infected 
persons  
n = 315
Non-infected control 
group 
n = 25
Age Me (IQR) yrs 40 (35–48) 37 (24–52) p = 0.0007
Sex male n (%)
female n (%)
224 (71)
91 (29)
118 (55)
135 (45)
BMI Me (IQR) [kg/m2] 24 (21–26) 25 (22–28) p = 0.002
Osteoporosis n (%) 
odds ratio (OR);  
95% Cl; p
relative risk (RR);  
95% Cl; p 
8 (9)*
7.66; 1.98–29.6;  
p = 0.0010
7.04; 1.98–25.97; 
p = 0.0019
3 (1)#
on ARV n (%) 249 (79) Not related
*DXA in 87 persons; #DXA in 230 persons
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Table III. Results of genotypic assay (SNP, single nucleotide polymorphism) and minor allele frequency (MAF)
Tabela III. Wyniki badań genetycznych (single nucleotide polymorphism, SNP) oraz częstość alleli mniejszościowych (minor 
allele frequency, MAF)
SNP (rs) Gene Chromosome Allele frequency n (%) MAF-all MAF-HIV(+) MAF-controls MAF dsSNP*
rs1800012 COL1A1 17 n = 557 A = 0.1570 A = 0.1515 A = 0.164 A = 0.0911
AA 1 (0.2) p = 0.63^
AC 173 (31)
CC 383 (68.8)
A 175 (16)
C 939 (84) HWE# p < 0.001
rs1544410 VDR1/Bsml 12 n = 563 T = 0.3490 T = 0.3742 T= 0.3182 T = 0.2959
TT 63 (11) p = 0.17
CT 267 (47
CC 233(42)
T 393 (35)
C 733 (65)
rs731236 VDR1/Taql 12 n = 552 G = 0.3460 G = 0.3738 G = 0.3127 G = 0.2766
GG 60 (11) p = 0.14
AG 262 (47)
AA 230 (42)
G 382 (35)
A 722 (65)
rs2077647 ER1 6 n = 559 C = 0.3220 C = 0.3480 C = 0.2905 C = 0.4665
CC 57 (10) p = 0.14
CT 246 (44)
TT 256 (46)
C 360 (32)
T 758 (68)
rs3020314 ER1 6 n = 560 T = 0.4946 T = 0.5065 T = 0.4802 T = 0.3838
TT 147 (26) p = 0.55
CT 260 (47)
CC 153 (27)
T 554 (49)
C 566 (51)
rs1884051 ER1 6 n = 564 G = 0.3085 G = 0.3344 G = 0.2767 G = 0.4908
GG 51 (9) p = 0.13
AG 246 (44)
AA 267 (47) 
G 348 (31)
A 780 (69)
rs4355801 OPG 8 n = 562 G = 0.4511 G = 0.4469 G = 0.4562 G = 0.2756
(TNFRSF11B) GG 109 (19) p = 0.85
AG 289 (52)
AA 164 (29)
G 507 (45)
A 617 (55)
rs9630182 PTH 11 n = 562 T = 0.3496 T = 0.3694 T = 0.3254 T = 0.4609
TT 64 (11) p = 0.28
CT 265 (47)
CC 233 (42)
T 393 (35)
C 731 (65) HWE p < 0.05
rs3736228 LRP5 11 n = 555 T = 0.1009 T = 0.0945 T = 0.1089 T = 0.1160
TT 6 (1) p = 0.47
CT 100 (18)
CC 449 (81) 
T 112 (10)
C 998 (90)
rs3018362 RANK 18 n = 534 A = 0.4401 A = 0.4433 A = 0.4362 A = 0.3750
AA 115 (22) p = 0.88
AG 240 (45)
GG 179 (33)
A 470 (44)
G 598 (56)
rs700518 CYP19A1 15 n = 558 C = 0.5493 C = 0.5863 C = 0.514 C = 0.3259
TT 121 (22) p = 0.20
CT 261 (47)
CC 176 (31)
C 613 (55) 
T 503 (45)
*www.ncbi.nlm.nih.gov/SNP/; ^for MAF-HIV(+) and MAF-controls; #HWE — Hardy-Weinberg Equilibrium
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Table IV. SNPs results in all patients, HIV-infected (HIV(+)) persons and healthy control and association with osteoporosis
Tabela IV. Wyniki badań SNPs u wszystkich pacjentów, zakażonych HIV [HIV(+)] oraz grupy kontrolnej (Controls) oraz ich 
związek z osteoporozą
SNPs 
Gene/rs/genotype
All 
n (%)
HIV(+) 
n (%)
Controls 
n (%)
Osteoporosis* 
n (%)
Without 
osteoporosis 
n (%)
COL1A1/rs1800012
AA
AC
CC
A
nA
n = 557
1 (0.2)
173 (31) 
383 (68,8)
174 (31)
383 (69)
n = 307
0 (0)
93 (30)
214 (70)
p = 0.48
93 (30)
214 (70) 
p = 0.59 
n = 250
1 (0.4)
80 (32)
169 (67,6)
81 (32)
169 (68)
n = 11
0
6 (55)
5 (45)
p = 0.2461
6 (55)
5 (45) 
p = 0.0940 
n = 300
0
92 (31)
208 (69)
92 (31)
208 (69)
VDR1/ rs1544410
TT
CT
CC
T
nT
n =563
63 (11)
267 (47) 
233 (42)
332 (58) 
231 (42)
n = 310
42 (14)
148 (48)
120 (39)
p = 0.0984
190 (61)
120 (39)
p = 0.232
n = 253
21 (8) 
119 (47)
113 (45)
142 (56) 
111 (44) 
n = 11
1 (9)
4 (36)
6 (55)
p = 0.7061
5 (45)
6 (55)
p = 0.8081
n = 304
30 (10)
146 (48)
128 (42)
176 (58)
128 (42)
VDR2/rs731236
GG
AG
AA
G
nG
n = 552
60 (11)
262 (47)
230 (42)
322 (58)
230 (42)
n = 301
39 (13)
147 (49)
115 (38)
p = 0.0898
186 (62)
115 (38) 
p = 0.0709
n = 251
21 (8)
115 (46)
115 (46)
136 (54)
115 (46)
n = 11
1 (9)
4 (36)
6 (55)
p = 0.7491
5 (45)
6 (55)
p = 0.4615
n = 300
28 (9)
142 (47)
130 (44)
170 (57)
130 (43)
ER1/rs2077647
CC
CT
TT
C
nC
n = 559
57 (10)
246 (44)
256 (46)
303 (54)
256 (46)
n = 306
41 (13)
131 (43)
134 (44) 
p = 0.0222
172 (56)
134 (44)
p = 0.29533
n = 253
16 (6)
115 (46)
122 (48)
131 (52)
122 (48)
n = 11
3 (27.5)
3 (27.5)
5 (45)
p = 0.0798
6 (55)
5 (45)
p = 0.9266
n = 303
25 (8)
136 (45)
142 (47)
161 (53)
142 (47)
ER1/rs3020314
TT
CT
CC
T
nT
n = 560
147 (26)
260 (47)
153 (27)
407 (73)
153 (27)
n = 307
88 (29)
135 (44)
84 (27)
p = 0.3024
223 (73)
84 (27)
p = 0.09
n = 253
59 (27)
125 (23)
69 (50)
184 (73)
69 (27)
n = 11
4 (36)
6 (55)
1 (9) 
p = 0.2623
10 (91)
1 (9) 
p = 0.1492
n = 303
64 (21)
151 (50)
88 (29)
215 (71)
88 (29)
→
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ER1/rs1884051
GG
AG
AA
G
nG
n = 564
51 (9)
246 (44)
267 (47)
297 (53)
267 (47)
n = 311
38 (12)
132 (43)
141 (45)
p = 0.014
171 (55)
140 (45) 
p = 0.2574
n = 253
13 (5)
114 (45)
126 (50) 
126 (50)
127 (50)
n = 11
3 (28)
4 (36)
4 (36)
p = 0.0441
7 (64)
4 (36)
p = 0.4036
n = 303
21 (7)
133 (44)
149 (49) 
154 (51)
149 (49)
OPG/rs4355801
GG
AG
AA
G
nG
n = 562
109 (19)
289 (52)
164 (29)
399 (71)
164 (29)
n = 311
58 (19)
162 (52)
91 (29)
p = 0.8775
220 (71)
91 (29)
p = 0.9700
n = 251
51 (20)
127 (51)
73 (29)
178 (71)
73 (29)
n = 11
2 (18)
8 (73)
1 (9)
p = 0.30002
10 (91)
1 (9)
p = 0.1643
n = 302
63 (21)
154 (51)
85 (28)
217 (72)
85 (28)
PTH/rs9630182
TT
CT
CC
T
nT
n = 562
64 (11)
265 (47)
233 (42)
329 (58)
233 (42)
n = 310
36 (12)
157 (50) 
117 (38) 
p = 0.1272
193 (62)
117 (38) 
p = 0.047
n = 252
28 (11)
108 (43)
116 (46)
136 (54)
116 (46)
n = 11
1 (9)
7 (64)
3 (27)
p = 0.4608
8 (73)
3 (27)
p = 0.25277
n = 302
31 (10)
136 (45)
135 (45)
167 (55)
135 (45)
LRP5/rs3736228
TT
CT
CC
T
nT
n = 555 
6 (1)
100 (18)
449 (81)
106 (19)
449 (81)
n = 307
5 (2)
48 (16)
254 (83) 
p = 0.1132
53 (17)
254 (83)
p = 0.2211
n = 248
1 (0.4)
52 (20.6)
195 (79) 
53 (21)
195 (79)
n = 11
0 (0)
1 (9)
10 (91)
p = 0.6287
1 (9)
10 (91)
o = 0.3372
n = 300
1 (0.3)
62 (20. 7)
237 (79)
63 (21)
237 (79)
RANK/rs3018362
AA
AG
GG
A
nA
n = 534
115 (22)
240 (45)
179 (33)
357 (67)
177 (33)
n = 291
61 (21)
136 (47)
94 (32) 
p = 0.6578
199 (68)
92 (32) 
p = 0.4108
n = 243
54 (22)
104(47)
85 (35)
158 (65)
85 (35)
n = 9
2 (22)
4 (45)
3 (33)
p = 0.9914
7 (78)
2 (22)
p = 0.5749
n = 296
69 (23)
135 (46)
92 (31)
204 (69)
92 (31)
CYP19A1/rs700518
TT
CT
CC
C
nC
n = 558
121 (22)
261 (47)
176 (31)
437 (78)
121 (22)
n = 308
58 (19)
144 (47)
106 (34)
p = 0.1118
250 (81)
58 (19)
p = 0.069
n = 250
63 (25)
117 (47)
70 (28)
187 (75)
63 (25)
n = 11
2 (18)
5 (46)
4 (36)
p = 0.8381
9 (82)
2 (18)
p = 0.69
n = 300
70 (23)
144 (48)
86 (29)
230 (77) 
70 (23)
*DXA in 87 HIV(+) persons and 230 healthy control (total 317)
Table IV cont. SNPs results in all patients, HIV-infected (HIV(+)) persons and healthy control and association with osteoporosis
Tabela IV. cd. Wyniki badań SNPs u wszystkich pacjentów, zakażonych HIV [HIV(+)] oraz grupy kontrolnej (Controls) oraz 
ich związek z osteoporozą
SNPs 
Gene/rs/genotype
All 
n (%)
HIV(+) 
n (%)
Controls 
n (%)
Osteoporosis* 
n (%)
Without 
osteoporosis n (%)
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p = 0.024, respectively, see Table IV. In cases with 
confirmed osteoporosis the following genotypes were 
significantly more common: CC genotype for the ER1 
(rs2077647): OR = 4.17, p = 0.038 and ER1 rs1884051 GG 
genotype: OR = 5.04, p = 0.025. Additionally, A allele 
of the COL1A1 rs1800012 was more frequent in people 
with osteoporosis, but of borderline statistical signifi-
cance: OR = 2.71, p = 0.059. The results of analysis of the 
odds ratio and relative risk for major genetic variations 
are summarized in Table V. Estrogen ER1 rs2077647 and 
rs1884051 SNPs were more common both among cases 
with osteoporosis, and independently in HIV(+) cases.
Discussion
Increased incidence of osteoporosis in HIV-infected 
persons remains a significant concomitant health issue. 
In investigation on the causes of this phenomenon, 
alongside with the well-defined classic risk factors for 
osteoporosis, or immune activation pathways affecting 
bone metabolism, genetic factors must be considered. 
It should be noted, however, that no genetic factors 
associated with decreased bone mineral density in this 
group were clearly identified so far. 
Previous studies on the genetic osteoporosis risk 
factors focused mainly on the post-menopausal women. 
For example, in the Polish study the impact of gene 
polymorphism of collagen type 1 — COL1A1 on bone 
mineral density in postmenopausal women was negli-
gible. In our analysis, we have found the relationship 
between the COL1A1 rs1800012 A allele and osteopo-
rosis, although our result was of borderline statistical 
significance (p = 0.094). In addition, the frequency of 
minority allele in the cited study was 5.5%, while our 
data indicate the frequency of only 0.2%. The reason for 
such discrepancies may be linked to the selection of the 
control group: previous studies included mostly women, 
while in our groups there was a predominance of men. 
Despite numerous studies suggesting the influence 
of vitamin D receptor (VDR), osteoprotegerin (OPG), 
receptor for the LDL: LRP5, RANK or aromatase 
(CYP19A1) genetic variation on the bone mineral den-
sity, no such association was confirmed in our study. 
Lack of this association may be linked to the small num-
ber of patients with confirmed osteoporosis. Significant 
link between osteoporosis with genetic variability was 
obtained for 2 SNPs of the estrogen receptor type 1 — 
ER1: rs2077647 and rs 1884051.
Common presence of multiple genotypes associated 
with increased risk of lower bone mineral density in 
HIV infected patients and cases with osteoporosis may 
confirm the link between this variability and osteoporo-
sis. It should be noted, however that majority of patients 
with osteoporosis in our study were HIV patients: 8 out 
of 11 confirmed cases of osteoporosis; therefore the risk 
genotypes may be significant for this group.
Higher frequency alleles related to the increased risk 
of osteoporosis among HIV-infected cases, especially 
coding for the hormone receptors — estrogen or para-
thyroid hormones may be of notable clinical significance 
for these patients. Estrogen receptor gene variability 
was described not only in the context of osteoporosis, 
but also bone remodeling, bone reconstruction or re-
sistance to injury.
Limitations of our study was associated to the 
smaller number of DXA scans in a group of HIV-infected 
than in the control group which limited the association 
study. Also, to some extent the dominance of men in 
the group of people infected with HIV was a limiting 
factor, ideally similar study should be performed in 
the group of postmenopausal HIV-1 infected cases, 
however access to such a group is limited.
Conclusions
Frequency of allelic variation for the analysed SNPs as-
sociated with osteoporosis was similar in HIV-infected 
patients and uninfected persons. Distribution of several 
genotypes was notably different between the studied 
populations. Significantly higher frequency was noted 
among HIV infected patients for the genotype CC of 
ER1 rs2077647, GG of ER1 rs1884051 and PTH rs9630182 
Table V. Statistically significant differences between allels in studied groups
Tabela V. Statystycznie istotne różnice występowania poszczególnych alleli w badanych grupach
Group Gen/rs/genotype or allele OR ( 95% Cl); p RR (95% Cl); p 
HIV group ER1/rs2077647/CC 2.29 (1.25–4.19); p = 0.003 2.11 (1.22–3.68); p = 0.0072
Osteoporosis ER1/rs2077647/CC 4.17 (1.04–16.72); p = 0.038 3.31 (1.17–9.31); p = 0.064
HIV group ER1/rs1884051/GG 2.57 (1.33–4.94); p = 0.0016 2.37 (1.29–4.36); p = 0.002
Osteoporosis ER1/rs1884051/GG 5.04 (1.24–20.4); p = 0.025 3.94 (1.38–11.24); p = 0.043
HIV group PTH/rs9630182/T allele 1.4 (1.0–1.97); p = 0.024 1.15 (0.99–1.33); p = 0.029
Osteoporosis COL1A1/rs1800012/A allele 2.71 (0.8–9.11); p = 0.059 1.77 (1.01–3.13); p = 0.092
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T allele. Genotypes GG of ER1 rs1884051 and CC of ER1 
rs2077647 were also notably more common among cases 
with osteoporosis. Increased incidence of osteoporosis 
in HIV-infected compared to uninfected people are 
associated only with a limited relationship with the in-
vestigated single nucleotide polymorphisms, although 
the variation in the estrogen receptor ER1 rs1884051 
and ER1 rs2077647 was significantly associated with 
osteoporosis and more common in HIV infection.
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